Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Innovent Biologics Inc.

www.innoventbio.com/en/

Latest From Innovent Biologics Inc.

Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs

Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.

Deals Business Strategies

Better Together: New Deal Adds Weight To China Biosimilar/Biobetter Swap

Perhaps encouraged by the recent successful initial public offering of Innovent Bio, more biologics developers in China are turning towards innovative biologics and away from traditional biosimilars.

China South Korea

Strong Innovent IPO Restoring Faith In HK Biotech Listings?

Suzhou-based Innovent Bio becomes the fourth biotech from mainland China to go public in Hong Kong, and its strong first-day performance may have given the seemingly spooked market so far for such companies a shot of confidence.

Hong Kong Financing

A Safe Harbor For Biotechs? Ascletis, BeiGene Mark Early Wins For HK Exchange

The market debuts of BeiGene and Ascletis on the new Hong Kong Stock Exchange’s Biotech section could further encourage other Chinese biotech companies as they seek to draw in a wider pool of investors and focus on the promising domestic sector.

Hong Kong Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Innovent Biologics Inc.
  • Senior Management
  • Michael Yu, PhD, Chmn. & CEO
    Ronnie Ede, CFO
    Blake Salisbury, PhD, VP, Bus. Dev.
    Xiaolin Liu, MD, SVP, R&D
    Qinwei Zhou, PhD, COO
  • Contact Info
  • Innovent Biologics Inc.
    Phone: 512 69566088
    168 Dongping St., Suzhou Industrial Park
    Suzhou, 215123
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register